Abstract:Background: Multiple studies have confirmed that programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) is widely expressed in gestational trophoblastic neoplasia (GTN) tissues. Therefore, immune checkpoint inhibitors may be an option for the treatment of recurrent and drug-resistant GTN. Case: Four patients with recurrent or drug-resistant GTN who were treated with PD-1/PD-L1 checkpoint inhibitor agents combined with chemotherapy were reported. The mean age of recurrence was 45.8 years (35-56 years), including three cases of choriocarcinoma (CC) and one case of invasive mole (IM). International Federation of Gynecology and Obstetrics (FIGO) prognosis score: ≤6 (low risk) in one case, 7-12 (high risk) in one case, ≥13 (very high risk) in two cases. There were two cases of lung metastasis and one case of vulvar and inguinal lymph node metastasis. One of the four patients underwent total hysterectomy and one patient underwent resection of lung metastases. All the four patients received comprehensive treatment of immunotherapy combined with chemotherapy after relapse, among which one patient achieved complete response (CR), two patients achieved partial response (PR), and one patient developed progressive disease (PD). Three patients who achieved PR or CR were maintained by single agent immunotherapy after combination therapy, and there was no disease recurrence during follow-up. One patient with PD also achieved CR after using salvage chemotherapy after recurrence, and there was no disease recurrence during follow-up. During the treatment, four patients had different degrees of immune-related adverse reactions, all of which were grade I-II, and no severe adverse reactions were found. Conclusion: Immune checkpoint inhibitors combined with chemotherapy has an impressive therapeutic effect on recurrent or drug-resistant GTN with mild adverse reactions, which can be used as a treatment option for such patients. However, due to the lack of large sample data support, the specific time and treatment course of its use, long-term use of adverse reactions and whether it affects fertility function remain to be solved.

Gestational trophoblastic neoplasm in a patient with end-stage renal failure (ESRF): the challenges and lessons learnt

Clinical analysis of recurrent gestational trophoblastic neoplasia

Diagnosis and management of or recurrent resistant gestational trophoblastic neoplasia

Gestational Trophoblastic Neoplasia with Extrauterine Metastasis but Lacked Uterine Primary Lesions: a Single Center Experience and Literature Review

Hepatic Toxicity Following Actinomycin D Chemotherapy in Treatment of Familial Gestational Trophoblastic Neoplasia: A Case Report.

Current chemotherapeutic options for the treatment of gestational trophoblastic disease

Analysis of Clinical Characteristics and Outcomes in 7 Patients with Re-recurrent Gestational Trophoblastic Neoplasia.

Evolution of Treatment Strategies for Gestational Trophoblastic Neoplasia: Chemotherapy, Immunotherapy, and Molecular Targeted Therapy

Diagnosis and Treatment of Gestational Trophoblastic Neoplasia

Ema-Co Chemotherapy for High-Risk Gestational Trophoblastic Neoplasia: A Clinical Analysis of 54 Patients

Update on the diagnosis and management of gestational trophoblastic disease

Diagnosis and management of gestational trophoblastic disease: 2021 update

The 16-Year Experience in Treating Low-Risk Gestational Trophoblastic Neoplasia Patients with Failed Primary Methotrexate Chemotherapy

Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management

Management of trophoblastic tumors : review of evidence, current practice, and future directions

Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets

Management and Prognostic Analysis of Patients with Gestational Trophoblastic Neoplasia (GTN) in FIGO Stage IV and Its Special Type

Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug-resistant gestational trophoblastic neoplasia: Four case reports and literature review

Gestational trophoblastic disease: an update

Review of current literature on gestational trophoblastic neoplasia

Comparison of Different Therapeutic Strategies for Complete Hydatidiform Mole in Women at Least 40 Years Old: a Retrospective Cohort Study.